Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1325 • ACR Convergence 2025
Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee¹, Punyasha Roul², Grant Cannon³, Gary Kunkel⁴, Beth Wallace⁵, Isaac Smith⁶, John Richards⁷, Katherine Wysham⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Joshua Baker¹³, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁵Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁶Duke University Hospital, Durham, NC, ⁷Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁸VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: The mechanisms of heart failure (HF) risk in RA remain incompletely understood. HF with preserved ejection fraction (HFpEF) is over-represented in RA, which may…
Abstract Number: 1309 • ACR Convergence 2025
Transcriptomic biomarkers of progression from undifferentiated arthritis to rheumatoid arthritis
Christina Printzis¹, Keerthana Nagesh Prabhu², Regina Sakalyte³, Sigita Stropuviene³ and Damini Jawaheer¹, ¹Northwestern University, Chicago, IL, ²Washington University in St. Louis, St Louis, MO, ³Vilnius University, Faculty of Medicine, Institute of Clinical Medicine, Clinic of Rheumatology, Orthopedics Traumatology and Reconstructive Surgery, Vilnius, Lithuania
Background/Purpose: A broad range (6-55%) of patients classified as having undifferentiated arthritis (UA) tend to progress to rheumatoid arthritis (RA), suggesting that UA in these…
Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
William Koch¹, Donald Anthony², Janeen Leon² and Nora G. Singer², ¹University Hospitals Parma Medical Center, Parma, OH, ²The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
Abstract Number: 1034 • ACR Convergence 2025
Healthy Dietary Patterns and Risk of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Elena Joerns¹, Jeffrey Sparks², Cynthia Chelf¹, Cynthia Crowson³, John Davis¹ and Vanessa Kronzer¹, ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Healthy dietary patterns are associated with many health benefits, including lower cardiovascular disease, mortality, and rheumatoid arthritis (RA) disease activity. Therefore, we aimed to…
Abstract Number: 0978 • ACR Convergence 2025
IL-17A+ HLA-DR-CCR6+ regulatory T cells: Dual role in T cell suppression and synovial inflammation in arthritis.
Bennie Heeswijk¹, Margot Bongenaar¹, Nadine Davelaar¹, Pascal de Jong¹, Hannah den Braanker¹, Radboud Dolhain¹ and Erik Lubberts², ¹Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, ²Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Regulatory T cells (Tregs) are essential for maintaining immune tolerance and limiting excessive immune responses. However, Tregs show high levels of heterogeneity and plasticity,…
Abstract Number: 0867 • ACR Convergence 2025
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of…
Abstract Number: 0797 • ACR Convergence 2025
Spatial transcriptomics identifies density-sensing fibroblasts in synovial lining
Sonia Presti¹, Kseniia Anufrieva², Ce Gao³, Sean Prell², Philip Blazar², Jeffrey Lange², Morgan Jones², Mihir Wechalekar⁴, Michael Brenner², Ilya Korsunsky⁵, Shideh Kazerounian² and Kevin Wei⁶, ¹Standford University, Stanford, ²Mass General Brigham, Boston, ³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Division of Genetics, DOM, BWH; Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: The synovial lining is crucial for joint homeostasis, forming a barrier and producing lubricants through specialized fibroblasts. These fibroblasts differ from sublining fibroblasts, which…
Abstract Number: 0495 • ACR Convergence 2025
Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
MIDHUN SAKRAVARTHY JALANATHAN¹, Mehdi Ali Mirza¹, Vijaya prasanna Parimi², Seethalakshmi S¹ and Tejaswini Ramineni³, ¹ESIC Medical College and Hospital, Sanathanagar, Hyderabad, Telangana, India, ²ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, ³Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India
Background/Purpose: Iguratimod (IGU), an oral synthetic disease-modifying antirheumatic drug (DMARD), has shown significant efficacy and safety in rheumatoid arthritis (RA) when combined with methotrexate (MTX)…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 0462 • ACR Convergence 2025
Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
Sayuli Bhide¹, Hannah Brubeck², Punyasha Roul³, Aaron Baraff², Bryant England⁴, Nadine El-Ayache¹, Grant Cannon⁵, Namrata Singh⁶, Gary Kunkel⁷, Ted Mikuls⁴, Dolores Shoback⁸, Kaleb Michaud⁴, Patti Katz⁹, Jose Garcia¹⁰, Ariela Orkaby¹¹, Joshua Baker¹² and Katherine Wysham¹³, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³UNMC, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶University of Washington, Bellevue, WA, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ⁹UCSF, San Rafael, CA, ¹⁰VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹¹Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Boston, MA, ¹²University of Pennsylvania, Philadelphia, PA, ¹³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty predicts mortality in RA. In the general population, males have a higher risk of death than females despite lower levels of frailty.1 We…
Abstract Number: 0445 • ACR Convergence 2025
GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis
Giorgos Loizidis and Ross summer, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Obesity significantly increases cardiovascular morbidity and mortality in rheumatoid arthritis (RA), yet effective strategies for managing obesity-related risks in this population remain limited. Glucagon-like…
Abstract Number: 0379 • ACR Convergence 2025
Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
Rosa Maria Morlà Novell¹, Enrique González-Dávila², Beatriz Frade Sosa³, Maria López-Lasanta⁴, Noemí Busquets Pérez⁵, Marta Valls Roc⁶, Meritxell Sallés Lizarzáburu⁷, Georgina Salvador Alarcón⁸, Virginia Ruiz-Esquide⁹, Lola Tobalina Mastre¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí⁹, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Dr Trueta, Girona, Sudan, ⁷Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁸Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁰IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…
Abstract Number: 0215 • ACR Convergence 2025
Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients
Alexandra Kobza¹, Camille Bourgeois², Olivier Fogel³, Maxime Dougados⁴ and Anna Molto⁵, ¹University of Calgary, North Vancouver, BC, Canada, ²Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ³AP-HP, Paris, France, ⁴Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁵Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), face elevated risk for comorbidities that complicate disease management. Although rheumatology societies…
Abstract Number: 0147 • ACR Convergence 2025
Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
cécile gaujoux-viala¹, adeline Ruyssen-Witrand², Laurent arnaud³, clélia Bignon-Favary⁴, Lauren Inchboard⁴ and Bruno Fautrel⁵, ¹Department of Rheumatology - CHU Nîmes, IDESP UM¹³¹⁸  INSERM – Univ. Montpellier, Nîmes, France, Nîmes, France, ²Department of Rheumatology, C.H.U. de Toulouse, CIC ¹⁴³⁶, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, Toulouse, France, ³Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France, ⁴Horiana, Statistiques, Bordeaux, France, Bordeaux, France, ⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: A total of 98.8% of French citizens are registered in the National Health Data System (SNDS), which includes claims data of all reimbursed health-related…
Abstract Number: 0083 • ACR Convergence 2025
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
Pedro Quevedo¹, Javier mora², william garcia², alejandra Solano², juliana Muñoz² and Daniela Lopez², ¹San Rafael Cinic University Hospital, Bogota, Distrito Capital de Bogota, Colombia, ²san rafael clinic universtity hospital, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Prevalence of depression in RA patients ranging from 10% to 25%, making it the most common psychiatric disorder in this population. The Plutchik Suicide…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].